Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | PIM1 | P11309 | 5/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499849 | 0.86 | PIM1 (0.49) | ALDH1A1PIM1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL16595532 | 0.86 | CA12 (0.50) | ALDH1A1PIM1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL29526778 | 0.85 | PIM1 (0.64) | ALDH1A1PIM1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL705754 | 0.85 | PIM1 (0.64) | ALDH1A1PIM1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL16795656 | 0.84 | CA9 (0.64) | ALDH1A1CA12CA9MCL1FLT3 | |
| SCHEMBL16708198 | 0.80 | CA12 (0.48) | ALDH1A1PIM1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL28748245 | 0.80 | KDM4E (0.51) | ALDH1A1CA12CA9FLT3KDM4E | |
| SCHEMBL29810733 | 0.80 | CA12 (0.48) | ALDH1A1PIM1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL6407371 | 0.79 | FLT3 (0.76) | ALDH1A1PIM1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL28044374 | 0.79 | PIM1 (0.56) | PIM1CSNK2A1CSNK2A2CSNK2BCSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100413882-C | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2008-08-27 | — | — | CN | claimed |
| CN-1578786-A | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2005-02-09 | — | — | CN | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| CN-114773302-B | Benzofuran derivative and medical application thereof | 中国药科大学 | 2024-04-02 | — | — | CN | disclosed |
| CN-117362313-A | Organic compound, organic electroluminescent material, OLED device and application thereof | 武汉天马微电子有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| CN-113840597-A | Integrated stress response pathway inhibitors | 普拉西斯生物技术有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
| WO-2021050555-A1 | COMPOSITIONS AND USES THEREOF | X-CHEM, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-0602598-A1 | 3-Phenylindolyl-, -benzofuranyl- and -benzothienyl- alkylcarboxanilides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1994-06-22 | — | — | EP | disclosed |
| US-4812471-A | Hypoglycemic 5-(isoxazolyl or isothiazolyl)-oxazolidine-2,4-diones | PFIZER INC. (US) | 1989-03-14 | — | — | US | disclosed |
| US-4753956-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1988-06-28 | — | — | US | disclosed |
| US-4689336-A | Hypoglycemic 5-substituted oxazolidine 2,4-diones | PFIZER INC. (US) | 1987-08-25 | — | — | US | disclosed |
| US-4565820-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1986-01-21 | — | — | US | disclosed |
| US-4431810-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4342771-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-08-03 | — | — | US | disclosed |
| US-4009994-A | Process and product of optical brightening with quaternized benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1977-03-01 | — | — | US | disclosed |
| US-3940417-A | Quaternised benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885PIM1 2022/4885CSNK2A1 2515/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885PIM1 2022/4885CSNK2A1 2515/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | ALDH1A1 2231/4885PIM1 3365/4885CSNK2A1 537/4885 |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885PIM1 2022/4885CSNK2A1 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.